By Rita C. Peters Researchers continue to report exciting new discoveries in science and medicine that have the potential to improve life and address challenges facing society. The intersection of scientific opportunity and business profitability can, however, lead to ethical conflicts. Emerging scientific methods such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome editing technology, which can be used to modify genes in living cells and organisms, offer the promise of correcting genetic mutations to treat genetic causes of disease. Researchers and ethicists generally agree that gene editing methods are suitable for research applications, but not for reproductive purposes. Concerns about the misuse of gene-editing processes were realized when a scientist in China announced in November 2018 that he used CRISPR techniques to edit the genes in human embryos of twin girls with the intention of protecting them against the human immunodeficiency virus. This controversial work was denounced by scientists worldwide; in December 2019, a court in China sentenced the scientist to three years in prison for working outside the boundaries of scientific and medical ethics. This experiment illustrates the ethical, safety, and legal issues associated with promising new scientific discoveries, and many unanswered questions associated with their long-term use. FDA has Click Here For Complete Article Text
|
||||||||||||||||||
| Application Sequencing | ||||||||||||||||||
|
|
||||||||||||||||||
| Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|
|
|||||||||||